- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07649577
Generative AI for Medication Counselling and Adherence in Community Pharmacies
Human-AI Collaboration in the Pharmacy: A Cluster Randomized Controlled Trial of Generative AI for Medication Counselling and Adherence
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Amman, Jordan
- Petra University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Patient Eligibility Criteria
Inclusion Criteria:
Adults aged 18 years or older. Presenting with a new prescription or a refill for a chronic medication requiring counseling within one of the following classes: antihypertensives, oral antidiabetics, lipid-lowering agents, anticoagulants, or inhaled maintenance therapies.
Willing and able to provide informed consent.
Exclusion Criteria:
Presence of acute infections. Diagnosis of psychiatric disorders or oncological conditions. Presence of severe acute illness requiring urgent medical referral. Cognitive impairment precluding informed consent. Hearing or communication barriers that prevent interview completion without the presence of a caregiver.
Inability to provide a follow-up phone number for the 30-day adherence assessment.
Pharmacy and Pharmacist (Cluster) Eligibility Criteria
Inclusion Criteria:
Pharmacies legally registered in Jordan, providing routine prescription dispensing services, having at least one licensed pharmacist available during recruitment hours, and agreeing to participate for the full trial period.
Licensed pharmacists with a minimum of 2 years of clinical experience, working in participating pharmacies, providing direct patient counseling, and consenting to take part in the study.
Exclusion Criteria:
Pharmacies that are already using structured AI-assisted counseling tools as part of their routine practice.
Pharmacists on temporary placement for less than one month. Pharmacists not involved in patient-facing counseling.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Intervention arm procedures
For all eligible patients in the intervention arm, the pharmacist performed the standard patient assessment and determined which medicine(s) needed counselling.
Then, the pharmacist input a prompt in a de-identified format into ChatGPT®.
The prompt was a request for an easy-to-understand counselling document with information regarding the indications for the medication, dosage, schedule, route, course, missed doses, possible side effects, important precautions, storage, and advice on taking the medicine as prescribed (Appendix A).
The pharmacist ensured that the content generated by the AI was accurate and clear, making corrections where necessary, and then gave verbal counselling to the patient.
|
For all eligible patients in the intervention arm, the pharmacist performed the standard patient assessment and determined which medicine(s) needed counselling. Then, the pharmacist input a prompt in a de-identified format into ChatGPT®. The prompt was a request for an easy-to-understand counselling document with information regarding the indications for the medication, dosage, schedule, route, course, missed doses, possible side effects, important precautions, storage, and advice on taking the medicine as prescribed (Appendix A). The pharmacist ensured that the content generated by the AI was accurate and clear, making corrections where necessary, and then gave verbal counselling to the patient. The AI output was never provided to the patients without pharmacist evaluation. It is worth noting that pharmacists could also reject the AI output as inaccurate, insufficient, hazardous, and inappropriate altogether. Reproducibility was ensured through documenting the date and time, prompt te
Autres noms:
|
|
Aucune intervention: Control arm procedures
Pharmacies randomized to the control arm continued to provide usual medication counselling according to their standard routine practice, without access to the AI prompt templates or study AI workflow.
Control pharmacists used their usual professional references, as would occur in routine care, but they were not trained in or asked to use ChatGPT® during the trial period.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Applicable Counseling Domains Provided Correctly
Délai: day 0
|
Defined as the proportion of clinically applicable counseling domains communicated accurately during the encounter, compared with a medication-specific reference sheet.
Scored on a 0-100 scale, calculated as (Number of applicable domains correctly informed / Total number of applicable domains) x 100.Correctness score= (Number of applicable domains
|
day 0
|
|
Percentage of Essential Counseling Domains Addressed
Délai: Day 0
|
Defined as the proportion of essential counseling domains that were addressed during the encounter.
Scored on a 0-100 scale, calculated as (Number of applicable domains addressed / Total number of applicable domains) x 100.
|
Day 0
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Counseling Deficiencies Categorized by Clinical Severity
Délai: Day 0
|
The frequency of omitted or incorrect counseling information, independently assessed by a panel of pharmacists using a 3-point scale: Low Severity (minor wording issues), Moderate Severity (errors leading to sub-therapeutic effects), and High Severity (errors with high potential for significant patient harm).
|
Day 0
|
|
Score on the General Medication Adherence Scale (GMAS)
Délai: 30 Days Post-Encounter
|
Medication adherence assessed via telephone follow-up using the continuous total score from the General Medication Adherence Scale (GMAS).
Higher scores indicate better medication adherence.
|
30 Days Post-Encounter
|
|
Number of Participants Achieving Good Adherence
Délai: 30 Days Post-Encounter
|
The number of participants meeting the validated threshold for "good adherence" based on their GMAS survey responses.
|
30 Days Post-Encounter
|
|
Total Score on the Immediate Patient Understanding (Teach-Back) Assessment
Délai: Day 0
|
A brief interviewer-administered understanding assessment based on teach-back principles.
Scores range from 0 to 4, with higher scores indicating a better understanding of the medication.
|
Day 0
|
|
Total Score on the Patient Satisfaction Questionnaire
Délai: Day 0
|
A questionnaire covering clarity, usefulness, confidence, and overall satisfaction.
Total scores range from 5 to 25, with higher scores indicating greater patient satisfaction.
|
Day 0
|
|
Time Spent on Face-to-Face Counseling
Délai: Day 0
|
Total face-to-face counseling time measured in minutes using audio timestamps from the start of counseling to completion.
|
Day 0
|
|
Number of Encounters Based on AI Output Acceptance Level
Délai: Day 0
|
The proportion of encounters in which the AI-generated counseling output was fully accepted, edited before delivery, or rejected outright by the pharmacist.
|
Day 0
|
|
Number of AI-Related Discrepancies Identified
Délai: Day 0
|
The frequency of detected AI inaccuracies prior to counseling, such as omitted counseling points, overly technical wording, or incomplete missed-dose advice.
|
Day 0
|
|
Number of Clinical Near Misses and Safety Incidents
Délai: Day 0
|
The number of encounters featuring a "near miss" (an AI error identified and corrected by the pharmacist before reaching the patient) or an "incident" (inaccurate information that actually reached the patient).
|
Day 0
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Abdel-Qader, D. H., Al Meslamani, A. Z., Lewis, P. J., & Hamadi, S. (2021). Incidence, nature, severity, and causes of dispensing errors in community pharmacies in Jordan. International journal of clinical pharmacy, 43(1), 165-173. https://doi.org/10.1007/s11096-020-01126-w Abdel-Qader, D. H., et al. (2024). A comprehensive analysis of public satisfaction: Community pharmacists' pandemic preparedness in Jordan. Journal of Applied Pharmaceutical Science, 14(8), 160-168. Abdel-Qader, D. H., et al. (2025). Drug-Drug interaction management among pharmacists in Jordan: A national comparative survey. Pharmacy, 137. https://doi.org/10.3390/pharmacy13050137 Abu Hammour, K., et al. (2023). ChatGPT in pharmacy practice: A cross-sectional exploration of Jordanian pharmacists' perception, practice, and concerns. Journal of Pharmaceutical Policy and Practice, 16(1), 115. Ali, S., Shimels, T., & Bilal, A. I. (2019). Assessment of patient counseling on dispensing of medicines in outpatient pharmacy of Tikur-Anbessa Specialized Hospital, Ethiopia. Ethiopian journal of health sciences, 29(6), 727. Campbell, M. K., et al. (2012). Consort 2010 statement: Extension to cluster randomised trials. BMJ, 345. Chan, A.-W., et al. (2015). SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Revista Panamericana de Salud Pública, 38, 506-514. Elayeh, E. R., et al. (2019). Use of secret simulated patient followed by workshop based education to assess and improve inhaler counseling in community pharmacy in Jordan. Pharmacy Practice (Granada), 17(4). Fattah, F. H., et al. (2025). Comparative analysis of ChatGPT and Gemini (Bard) in medical inquiry: A scoping review. Frontiers in digital health, 7, 1482712. FIP, I. P. F. (2021). Medication review and medicines use review: A toolkit for pharmacists Colophon. FIP, I. P. F. (2025). An artificial intelligence toolkit for pharmacy: An introduction and resource guide for pharmacists. (March). Hammad, E. A., et al. (2022). Feasibi
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Maladies vasculaires
- Processus pathologiques
- Attributs de la maladie
- Maladies métaboliques
- Maladies du système immunitaire
- Maladies des voies respiratoires
- Maladies pulmonaires
- Troubles du métabolisme du glucose
- Maladies bronchiques
- Maladies pulmonaires obstructives
- Hypersensibilité respiratoire
- Hypersensibilité immédiate
- Hypersensibilité
- Troubles du métabolisme lipidique
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Maladie pulmonaire obstructive chronique
- Hypertension
- Asthme
- Maladies cardiovasculaires
- Diabète sucré
- Dyslipidémies
- Maladie chronique
Autres numéros d'identification d'étude
- Petrauniversity
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .